Shafique Virani - Aug 15, 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Business Officer
Signature: /s/ Jonathan Golightly, attorney-in-fact
Stock symbol: RXRX
Transactions as of: Aug 15, 2022
Transactions value $: -$330,888
Form type: 4
Date filed: 8/17/2022, 06:35 PM
Previous filing: May 18, 2022
Next filing: Sep 16, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Tax liability	-$7.94K	-613	-0.59%	$12.96	104K	Aug 15, 2022	Direct	F1
transaction	RXRX	Class A Common Stock	Options Exercise	$55.5K	+25K	+24.09%	$2.22^*	129K	Aug 16, 2022	Direct	F2
transaction	RXRX	Class A Common Stock	Sale	-$378K	-30K	-23.3%	$12.61	98.8K	Aug 16, 2022	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Options Exercise	$0	-25K	-3.64%	$0.00	662K	Aug 16, 2022	Class A Common Stock	25K	$2.22	Direct	F2, F4
holding	RXRX	Stock Option (Right to Buy)						80.5K	Aug 15, 2022	Class A Common Stock	0	$11.40	Direct	F5
holding	RXRX	Stock Option (Right to Buy)						5.44K	Aug 15, 2022	Class A Common Stock	0	$11.40	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2	Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person
F3	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.06 to $12.96 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F4	One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F5	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.